BioSpace News Archive

Paragon 28, Inc. (NYSE: FNA) (“Paragon”) announced today the commencement of a proposed underwritten public offering of 6,500,000 shares of its common stock, consisting of 3,750,000 shares offered by Paragon and 2,750,000 shares offered by certain selling securityholders.

STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that it will host a conference call to discuss its fiscal 2023 third quarter financial results at 10:00 a.m. ET on February 9, 2023.

Lannett Company, Inc. (NYSE: LCI) today announced that its Board of Directors approved a 1-for-4 reverse stock split of its issued and outstanding shares of common stock, effective at 5 p.m. Eastern Time on February 6, 2023.

Novavax, Inc. announced that it has granted a non-qualified stock option and restricted stock units to John C. Jacobs, its newly appointed President and Chief Executive Officer, as a material inducement for his entry into employment with Novavax, effective as of January 23, 2023, the first date of his employment with Novavax.

Pivotal study data published in The New England Journal of Medicine continues to highlight the efficacy, safety, and pharmacokinetic profile of efanesoctocog alfa, an investigational treatment for hemophilia A.

Medtronic plc recently became aware that TRC Capital Investment Corporation has made an unsolicited mini-tender offer to purchase up to 1,500,000 Medtronic ordinary shares, representing approximately 0.1% of the company’s outstanding ordinary shares.

GenKOre, Inc., a Korea-based biotech company with hypercompact CRISPR-Cas tools, announced that it has entered into a strategic research collaboration with a US-based biopharma company for the development of in vivo gene editing therapies.

Daewoong Pharmaceutical’s Fexuclue is attracting attention as a game changer in the global gastroesophageal reflux disease treatment market as it applied for approval in 11 countries across the world within one year after approval in Korea.

iNtRON Biotechnology has announced that it has completed the efficacy evaluation study of BAL200, a novel endolysin-based biologic for the treatment of ‘Inhalational Anthrax’, which was granted an Orphan Drug Designation by the US FDA.